Filter By Category
Archives
Share on -
ACAPATAMAB
Generic Name: ACAPATAMAB
ABSTRACT -
Acapatamab, also known as AMG 160, is an investigational half-life extended bispecific T-cell engager designed to bind prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T lymphocytes. By bringing cytotoxic T cells into close proximity with PSMA-expressing malignant cells, acapatamab may trigger targeted immune-mediated tumor-cell killing. It has been studied primarily in advanced or metastatic castration-resistant prostate cancer research settings. Acapatamab is not established as a routine approved treatment for general clinical use.
DOSAGE –
Acapatamab is an investigational oncology biologic and should only be administered under an approved clinical trial protocol or by qualified oncology specialists.
- Studied by intravenous administration in controlled clinical research settings.
- Dose-escalation and dose-expansion schedules vary by protocol, combination regimen, and patient cohort.
- Premedication, step-up dosing, hospitalization/observation, or monitoring may be required to reduce cytokine-release-related risk.
- No routine commercial dosage has been established for general medical use.
- Dose interruption, adjustment, or discontinuation may be required for clinically significant toxicity.
- Participants should follow all protocol-specific dosing, monitoring, laboratory testing, and follow-up instructions.
SIDE EFFECTS –
ALLRGIC REACTIONS–
Reported or potential side effects may include:
- Cytokine release syndrome, fever, chills, or flu-like symptoms
- Fatigue or weakness
- Nausea, vomiting, or diarrhea
- Headache
- Low blood pressure, dizziness, or fainting
- Injection or infusion-related reactions
- Low blood cell counts
- Infections
- Elevated liver enzymes or other laboratory abnormalities
- Muscle or joint pain
- Shortness of breath or cough
- Rash or itching
DRUG INTERACTIONS -
Formal interaction data are limited because acapatamab remains investigational. Caution should be exercised when used with:
- Other anticancer therapies that may increase immune, marrow, liver, or infection-related toxicity
- Immunosuppressive medicines or high-dose corticosteroids that may affect immune activity
- Medicines associated with cytokine release, infusion reactions, or overlapping inflammatory toxicity
- Live or live-attenuated vaccines unless specifically permitted by the protocol
- Anticoagulants or antiplatelet medicines when platelet counts are low or bleeding risk is present
- Other investigational drugs, herbal products, or supplements unless allowed by the trial protocol
Patients should inform healthcare providers about all prescription medicines, non-prescription medicines, vitamins, herbal products, vaccines, and supplements being used.
PRECAUTIONS –
- Use only in specialist oncology or clinical trial settings.
- Assess baseline blood counts, liver function, kidney function, infection status, tumor burden, and performance status before treatment.
- Monitor closely for cytokine release syndrome, infusion reactions, neurologic symptoms, infection, cytopenias, and liver enzyme abnormalities.
- Ensure access to emergency treatment and supportive care for severe infusion or immune-related reactions.
- Use caution in patients with active infection, significant immune suppression, uncontrolled cardiovascular disease, or poor general condition.
- Pregnancy and breastfeeding safety have not been established; effective contraception may be required in clinical trials.
- Patients should report fever, chills, confusion, shortness of breath, rash, dizziness, or rapidly worsening symptoms immediately.
WARNINGS –
- Acapatamab is investigational and has not been established for routine general medical use.
- Bispecific T-cell engagers can cause serious immune-mediated reactions, including cytokine release syndrome and neurologic events.
- Severe infections, cytopenias, hypotension, or organ dysfunction may occur and require urgent medical attention.
- Clinical use should be supervised by trained oncology personnel with access to emergency care.
- Keep out of reach of children.
- In case of severe reaction, difficulty breathing, fainting, confusion, or suspected overdose, seek immediate medical attention.
- Patients should report unusual symptoms or side effects to their healthcare provider or clinical investigator promptly.
Share on -
. Developed by